🇺🇸 NESP(Darbepoetin alfa) in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 17

Most-reported reactions

1. Dehydration — 3 reports (17.65%)
2. Condition Aggravated — 2 reports (11.76%)
3. Ileus — 2 reports (11.76%)
4. Muscular Weakness — 2 reports (11.76%)
5. Nausea — 2 reports (11.76%)
6. Pyrexia — 2 reports (11.76%)
7. Activities Of Daily Living Impaired — 1 report (5.88%)
8. Alanine Aminotransferase Increased — 1 report (5.88%)
9. Altered State Of Consciousness — 1 report (5.88%)
10. Anaemia — 1 report (5.88%)

Source database →

Frequently asked questions

Is NESP(Darbepoetin alfa) approved in United States?

NESP(Darbepoetin alfa) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NESP(Darbepoetin alfa) in United States?

Chong Kun Dang Pharmaceutical is the originator. The local marketing authorisation holder may differ — check the official source linked above.